Lindsey Shapiro, PhD,  science writer—

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly‘s antibody therapy donanemab, now Kisunla, for certain adults with Alzheimer’s disease. Specifically, Kisunla is indicated for patients with early symptomatic Alzheimer’s — to include individuals with mild cognitive impairment or mild dementia, and confirmed evidence of…

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 2 trial testing INmune Bio’s investigational treatment XPro1595 in people with Alzheimer’s disease. Regulators issued the hold in 2022 pending additional manufacturing information from INmune. The company addressed some of the FDA’s…

The U.S. Food and Drug Administration (FDA) has approved BrainSee, Darmiyan’s software for predicting the likelihood that a person with mild cognitive impairment (MCI) will progress to Alzheimer’s disease-associated dementia. Darmiyan believes the technology will help to screen and identify high-risk patients early, enabling a prompt start…

A tool called focused ultrasound, or FUS, may be a safe and promising way to help antibody-based treatments better reach the brain, and clear away toxic amyloid-beta protein clumps (aggregates), in people with Alzheimer’s disease. The approach involves using targeted sound waves to temporarily open up the selective blood-brain…

With November comes National Alzheimer’s Awareness Month, an annual effort to recognize the impact of the neurodegenerative disease in the U.S., where about 6.2 million people are affected by it. Each November, the Alzheimer’s Foundation of America (AFA) offers supporters a range of different ways to raise awareness…

An ongoing Phase 2/3 clinical trial testing Annovis Bio’s treatment candidate buntanetap in people with Alzheimer’s disease is expected to be fully enrolled next month, with trial data anticipated in March 2024, according to a company update. These estimations come after a recent six-week interim analysis of 107…

Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) significantly slows cognitive and functional decline in people with early Alzheimer’s disease, according to a new data analysis of a Phase 2b/3 clinical trial. The cognitive benefits were accompanied by a slower rate of brain shrinkage, a marker…

The PrecivityAD blood test from C2N Diagnostics significantly influences clinicians’ decisions about whether to treat people with cognitive impairments for Alzheimer’s disease. C2N, which sponsored the recent study, believes those findings offer robust real-world evidence that blood biomarker testing in the clinic helps to guide treatment decisions…

Quest Diagnostics has launched a consumer-initiated blood test for adults in the U.S. that assesses Alzheimer’s disease risk by measuring levels of certain forms of the amyloid beta protein, a known marker of the neurodegenerative disorder. Called AD-Detect, the test is now the first of its kind…

Racial and ethnic minority groups in the U.S. are underrepresented in Alzheimer’s disease neuroimaging research, but the gap may be starting to close, according to a review study. Efforts to address the issue in recent years have been associated with small increases in minority inclusion, but much work remains…